|
Hemato-oncology / Original Article
The characteristics of Korean elderly multiple myeloma patients aged 80 years or over
Sang Hwan Lee, Hee-Jeong Cho, Joon Ho Moon, Ji Yoon Jung, Min Kyoung Kim, Mi Hwa Heo, Young Rok Do, Yunhwi Hwang, Sung Hwa Bae
Korean J Intern Med. 2025;40(1):115-123. Published online January 1, 2025
Background/Aims: Multiple myeloma (MM) predominantly affects elderly individuals, but studies on older patients with MM are limited. The clinical characteristics and survival outcomes of patients with MM aged 80 years or over were retrospectively analyzed.
Methods: This retrospective multicenter st..
|
|
|
Hemato-oncology / Original Article
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
[corrected-article]
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Korean J Intern Med. 2023;38(2):238-247. Published online January 26, 2023
Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for pre..
|
|
|
Hemato-oncology / Original Article
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Korean J Intern Med. 2021;36(6):1459-1470. Published online October 21, 2021
Background/Aims: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment..
|
|
|
Hemato-oncology / Original Article
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Korean J Intern Med. 2019;34(6):1333-1346. Published online October 26, 2018
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
|
|
|
Review
Cellular immunotherapy in multiple myeloma
Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Sung-Hoon Jung, Duck Cho, Hye-Seong Park, Tan-Huy Chu, Hyun-Ju Lee, Hyeoung-Joon Kim, Sang-Ki Kim, Je-Jung Lee
Korean J Intern Med. 2019;34(5):954-965. Published online February 15, 2019
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic..
|
|
|
Hemato-oncology / Original Article
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med. 2017;32(4):722-730. Published online June 26, 2017
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population.
Methods: We reviewed the medical records of MM patients whose age was 40 ..
|
|
|
Hemato-oncology / Original Article
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med. 2017;32(4):711-721. Published online November 4, 2016
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis.
Methods: A total of 273 newly diagnosed MM pati..
|
|
|
Cardiology / Original Article
Association between left ventricular function and paraprotein type in patients with multiple
myeloma
Jeong-Eun Yi, Sung-Eun Lee, Hae-Ok Jung, Chang-Ki Min, Ho-Joong Youn
Korean J Intern Med. 2017;32(3):459-468. Published online April 6, 2016
Background/Aims: Multiple myeloma (MM)–associated cardiac damage, particularly according to the type of monoclonal (M) protein has not been elucidated. We sought to investigate relationship between elevated serum M protein levels and echocardiographic indices of cardiac structure and function in pa..
|
|
|
Hemato-oncology / Review
Recent advances in multiple myeloma: a Korean perspective
Junshik Hong, Jae Hoon Lee
Korean J Intern Med. 2016;31(5):820-834. Published online September 1, 2016
Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. App..
|
|
|
Hemato-oncology / Review
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Ho Sup Lee, Chang-Ki Min
Korean J Intern Med. 2016;31(5):809-819. Published online September 1, 2016
Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalido..
|
|
|
Hemato-oncology / Original Article
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun
Korean J Intern Med. 2015;30(5):675-683. Published online August 27, 2015
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) ..
|
|
|
Hemato-oncology / Review
Diagnosis and therapy of multiple myeloma
Antonio Palumbo, Chiara Cerrato
Korean J Intern Med. 2013;28(3):263-273. Published online May 1, 2013
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be se..
|
|
|
Original Article
A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
Hye Jung Chang, Jae Hoon Lee, Young Rok Do, Sung-Hwa Bae, Jung-Lim Lee, Seung Hyun Nam, Sung-Soo Yoon, Soo-Mee Bang
Korean J Intern Med. 2011;26(4):403-409. Published online November 28, 2011
Background/AimsThe clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment. Because the side effects of thalidomid..
|
|
|
Original Article
Predictive Value of Post-Transplant Bone Marrow Plasma Cell Percent in Multiple Myeloma Patients Undergone Autologous Transplantation
In Hye Hwang, Joo Seop Chung, Ho Jin Shin, Young Jin Choi, Moo Kon Song, Young Mi Seol, Goon Jae Cho, Bo Gwang Choi, Mun Ki Choi, Bo Kyung Choi, Kang Hee Ahn, Kyung Hwa Shin, Hee Sun Lee, Hyung Seok Nam, Jong Min Hwang
Korean J Intern Med. 2011;26(1):76-81. Published online March 2, 2011
Background/AimsAutologous stem cell transplantation (ASCT) has become the treatment of choice for patients with multiple myeloma (MM). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despit..
|
|
|
Case Report
Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
Myung-Hee Kang, Ji-Hyun Ju, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Ho-Cheol Kim, Gyeong-Won Lee
Korean J Intern Med. 2010;25(4):447-449. Published online November 27, 2010
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ..
|
|
|
Original Article
Elevation of Serum Ferritin is Associated with the Outcome of Patients with Newly Diagnosed Multiple Myeloma
Moo-Kon Song, Joo-Seop Chung, Young-Mi Seol, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho
Korean J Intern Med. 2009;24(4):368-373. Published online November 27, 2009
Background/AimsSerum ferritin is a marker of acute phase reactions and iron storage. In addition, hematologic malignancies are associated with elevated serum ferritin levels. Other studies have suggested that ferritin is a surrogate for advanced disease and has an impact on re..
|
|
|
Case Report
A Case of Nonsecretory Multiple Myeloma with Atypical Imaging Features
Hwa Yeon Lee, Seung Min Yoo, In Sup Song, Hyeon Yu, Jong Beum Lee, Jong Wook Shin, In Won Park
Korean J Intern Med. 2006;21(3):202-205. Published online September 30, 2006
Multiple myeloma usually shows homogeneous enhancement on contrast-enhanced Magnetic Resonance imaging (MRI), and is accompanied by a monoclonal gammopathy in serum or urine. We report a case of nonsecretory myeloma, the diagnosis was difficult due to the absence of a monoclonal gammopathy and th..
|
|
|
Original Article
Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study
Ock Bae Ko, Shin Kim, Hyeok Shim, Jung-Hun Lee, Jung-Min Ahn, Soon-Man Yoon, Min-Hyok Jeon, Il-No Do, So-young Lee, Yong Gil Kim, Sang We Kim, Sung-Bae Kim, Sang-Hee Kim, Jung Shin Lee, Wookun Kim, Chan-Jung Park, Hyun-sook Chi, Cheolwon Suh
Korean J Intern Med. 2005;20(3):237-242. Published online September 30, 2005
BackgroundAlthough high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an inst..
|
|
|
